Technical Articles: Reagent Chemistry, Synthesis & Bioscience Guides

FDA-approved Anticancer Drug Library: Research Guide

FDA-approved Anticancer Drug Library is a curated collection of clinically validated oncology compounds designed to accelerate cancer drug discovery, repurposing research, and mechanistic studies in both academic and pharmaceutical laboratory settings.

Selleck Reference Number
L8000
Compound Source
FDA-approved clinical oncology agents
Primary Application
High-throughput oncology drug screening and repurposing studies
Intended Users
Research scientists, lab managers, and oncology drug discovery teams

What Is the FDA-approved Anticancer Drug Library?

The FDA-approved Anticancer Drug Library (Lib412084) is a systematically assembled collection of small-molecule oncology therapeutics that have received regulatory approval from the U.S. Food and Drug Administration for the treatment of human cancers. Each compound in the library has demonstrated clinical efficacy and an established safety profile, making this library an exceptionally valuable resource for translational cancer research.

By focusing exclusively on FDA-approved agents, the library bridges the gap between basic science and clinical application. Researchers can study compounds whose pharmacokinetics, pharmacodynamics, and toxicology are already well-characterized in humans, thereby reducing the risk of late-stage attrition in drug development pipelines. This library is catalogued under the Selleck reference number L8000, ensuring cross-referencing with established oncology screening databases.

The library is suitable for a broad range of experimental formats, including cell viability assays, apoptosis studies, target engagement assays, and combination drug screening, all of which benefit from the clinical relevance of the included compounds.

Library Composition and Key Drug Classes

The FDA-approved Anticancer Drug Library encompasses compounds spanning diverse mechanistic classes, reflecting the breadth of clinically approved oncology therapeutics. These classes include, but are not limited to, kinase inhibitors, cytotoxic chemotherapeutics, monoclonal antibody-derived small molecules, hormone receptor modulators, proteasome inhibitors, PARP inhibitors, CDK inhibitors, and immune checkpoint pathway modulators where applicable in small-molecule format.

Kinase inhibitors represent one of the largest and most rapidly growing segments within the library, covering targets such as BCR-ABL, EGFR, HER2, VEGFR, ALK, ROS1, BRAF, MEK, PI3K, and mTOR. Cytotoxic agents include classical DNA-damaging compounds, antimetabolites, topoisomerase inhibitors, and microtubule-targeting agents. This mechanistic diversity allows researchers to run comparative screens across multiple oncology targets simultaneously.

The library is provided as pre-dissolved stock solutions in DMSO, formatted for direct use in plate-based assay systems. Each compound is supplied at a defined concentration and purity, with accompanying documentation to support experimental reproducibility and regulatory compliance in research settings.

Experimental Applications and Screening Protocols

The FDA-approved Anticancer Drug Library is optimized for high-throughput screening (HTS) workflows in oncology research. Its primary applications include phenotypic cancer cell line screening, target-based biochemical assays, drug repurposing investigations, and combination synergy studies.

For cell viability screening, researchers typically seed cancer cell lines in 96- or 384-well plates, treat with library compounds at one or more concentrations, and measure viability after 48–72 hours using luminescent, fluorescent, or colorimetric readouts such as CellTiter-Glo, resazurin, or MTT assays. Dose-response profiling can then be performed on hit compounds to generate IC50 values and selectivity indices against normal cell lines.

In drug repurposing workflows, the library enables systematic interrogation of approved agents against novel cancer indications or resistance mechanisms. Because all compounds have known human pharmacology, any repurposing hits can be prioritized for clinical investigation with a significantly compressed timeline compared to investigational new drugs. Researchers are advised to include appropriate positive and negative controls, validate DMSO vehicle concentrations below cytotoxic thresholds, and confirm primary hits in orthogonal assay formats to minimize false-positive rates.

Storage, Handling, and Quality Considerations

Proper storage and handling of the FDA-approved Anticancer Drug Library are essential to maintain compound integrity and ensure reproducible experimental outcomes. As with most small-molecule libraries dissolved in DMSO, compounds should be stored at –20°C or –80°C (as recommended per compound) in a desiccated environment to prevent moisture-induced degradation and freeze-thaw-related concentration drift.

Freeze-thaw cycles should be minimized. It is best practice to prepare working-concentration daughter plates from master stock plates, reserving the master stocks for long-term archiving. Each aliquot should be allowed to thaw at room temperature, briefly centrifuged to consolidate any condensed material, and used promptly after opening. Avoid prolonged exposure to light for photosensitive compounds.

Quality control documentation provided with the library typically includes purity data (HPLC or LC-MS), compound identity confirmation (NMR or mass spectrometry), and concentration verification. Researchers should review this documentation prior to initiating screens and retain records to support data integrity and potential publication requirements. Any discrepancies in compound appearance or solubility behavior compared to reference data should be reported to the supplier.

Procurement and Ordering Information

The FDA-approved Anticancer Drug Library is available from Aladdin Scientific under SKU Lib412084, cross-referenced with Selleck catalog number L8000. The library is offered in multiple plate formats and compound quantities to accommodate the scale requirements of different research programs, from pilot screens to full-scale HTS campaigns.

Prospective purchasers should contact Aladdin Scientific's technical sales team to discuss specific format requirements, including plate layout preferences, solvent options, and documentation packages. Custom concentration formats and subset libraries may be available upon request. Volume pricing and institutional purchasing agreements are available for high-volume or repeat orders, and procurement teams are encouraged to inquire about lead times and availability prior to study initiation to ensure uninterrupted experimental workflows.

For laboratory managers coordinating multi-user access to the library, it is recommended to establish an internal inventory management system, track aliquot usage and remaining volumes, and schedule timely reorders based on projected consumption rates to avoid experimental delays caused by stock depletion.

Frequently asked questions

What types of cancer targets are covered by the FDA-approved Anticancer Drug Library?

The library covers a broad spectrum of oncology targets including receptor and non-receptor tyrosine kinases (e.g., EGFR, HER2, BCR-ABL, ALK), serine/threonine kinases (e.g., BRAF, MEK, CDK), PI3K/mTOR pathway components, PARP, proteasome subunits, hormone receptors, topoisomerases, and microtubule dynamics. This mechanistic breadth makes the library suitable for multi-target comparative screening studies.

How should DMSO vehicle concentration be managed when using the library in cell-based assays?

DMSO concentrations in cell-based assays should generally be maintained at or below 0.1–0.5% (v/v) to avoid non-specific cytotoxicity that could confound screening results. Researchers should perform DMSO tolerance validation experiments on their specific cell lines prior to the main screen and include DMSO vehicle controls at equivalent concentrations in every assay plate to allow accurate background normalization.

Can the FDA-approved Anticancer Drug Library be used for drug repurposing research?

Yes, the FDA-approved Anticancer Drug Library is particularly well-suited for drug repurposing studies. Because all included compounds have established clinical pharmacology, any hits identified against new cancer indications or resistance mechanisms can be translated toward clinical evaluation far more rapidly than investigational compounds. This makes the library a cost-effective starting point for repurposing-driven oncology programs.

What quality control data is provided with the library?

The library is supplied with quality control documentation that typically includes HPLC or LC-MS purity data, compound identity confirmation by NMR or mass spectrometry, and concentration verification for each compound. Researchers should review all QC documentation before initiating screens and retain these records for data integrity and publication support purposes.

What plate formats are available for the FDA-approved Anticancer Drug Library?

The FDA-approved Anticancer Drug Library is offered in multiple plate formats to accommodate different screening scales. Researchers should contact Aladdin Scientific directly to confirm currently available format options, compound quantities per well, and any custom configuration possibilities for their specific experimental requirements.

References

  1. U.S. Food and Drug Administration. Hematology/Oncology (Cancer) Approvals and Safety Notifications. FDA.gov.
  2. Corsello SM, et al. The Drug Repurposing Hub: a next-generation drug library and information resource. Nature Medicine. 2017.
  3. Stokes JM, et al. A deep learning approach to antibiotic discovery. Cell. 2020. [Cited as a reference for ML-assisted compound library screening methodology.]
  4. Selleck Chemicals. L8000 FDA-approved Anticancer Drug Library product information.

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.

Categories: Technical Articles: Reagent Chemistry, Synthesis & Bioscience Guides

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.

Cite this article

Aladdin Scientific. "FDA-approved Anticancer Drug Library: Research Guide" Aladdin Knowledge Base, updated Nov 19, 2026. https://www.aladdinsci.com/us_en/faqs/fda-approved-anticancer-drug-library-research-guide-en.html
Was this article helpful? Yes No 2 out of 5 found this helpful

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.